[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544309":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":46,"responsibleParty":90,"collaborators":32,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":32,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":32,"enrollmentInfo":101,"targetDuration":32,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":79,"whyStopped":32,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Goal-Directed Fluid Therapy (GDFT) group","EXPERIMENTAL","Following anesthesia induction, patients will be connected to the FlowTrac\u002FVigileo monitoring system to facilitate the recording of pertinent hemodynamic parameters, including stroke volume variation (SVV), stroke volume, and cardiac output. Then, Norepinephrine Infusion Combined with Goal-directed Fluid Therapy will be administered. Efforts are made to sustain a mean arterial pressure (MAP) of ≥ 80 mmHg.",[13],"Drug: Goal-Directed Fluid Therapy (GDFT)",{"label":15,"type":16,"description":17,"interventionNames":18},"Regular Fluid Therapy group","ACTIVE_COMPARATOR","Patients will not undergo monitoring with the FlowTrac\u002FVigileo system throughout the whole procedure. Anesthesiologists will rely on their clinical expertise and intraoperative circulatory hemodynamic assessment to regulate fluid infusion rates and administer medications as necessary to sustain a mean arterial pressure (MAP) of ≥ 80 mmHg until the conclusion of the surgical procedure.",[19],"Drug: Regular Fluid Therapy",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Goal-Directed Fluid Therapy (GDFT)","Norepinephrine will be administered intravenously at a rate of 0.06 µg\u002Fkg\u002Fmin, followed by the implementation of fluid therapy guided by SVV until reaching our target. In instances where SVV ≤ 13%, indicative of adequate effective circulating blood volume, the fluid infusion rate will be adjusted to 1 ml\u002Fkg\u002Fh. Conversely, if SVV \\> 13%, denoting inadequate effective circulating blood volume, a rapid infusion of 1 ml\u002Fkg of crystalloid fluid will be administered over 2 minutes, with subsequent observation of fluid reactivity after a further 2-minute interval. This process is reiterated until SVV ≤ 13% is attained. Should SVV \\> 13% recurs during surgery, the aforementioned intervention is repeated.",[9],[27],"GDFT",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Regular Fluid Therapy","Anesthesiologists will rely on their clinical expertise and intraoperative circulatory hemodynamic assessment to regulate fluid infusion rates and administer medications as necessary",[15],null,[34],{"name":35,"affiliation":36,"role":37},"Diansan Su, Dr.","Department of Anesthesiology Renji Hospital","PRINCIPAL_INVESTIGATOR",[39,43],{"name":35,"role":40,"phone":41,"phoneExt":32,"email":42},"CONTACT","+862168383702","diansansu@yahoo.com",{"name":44,"role":40,"phone":41,"phoneExt":32,"email":45},"Muyan Shi, B.S.","jsqdsmy@163.com",[47,64,77],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"the First Affiliated Hospital of Zhengzhou University","NOT_YET_RECRUITING","Zhengzhou","Henan","450052","China","CN",{"type":56,"coordinates":57},"Point",[58,59],113.64861,34.75778,{"lat":59,"lon":58},[62],{"name":63,"role":40,"phone":32,"phoneExt":32,"email":32},"Jianjun Yang, Dr.",{"facility":65,"status":49,"city":66,"state":67,"zip":68,"country":53,"countryCode":54,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"General Hospital of Northern Theatre Command","Shenyang","Liaoning","110016",{"type":56,"coordinates":70},[71,72],123.43278,41.79222,{"lat":72,"lon":71},[75],{"name":76,"role":40,"phone":32,"phoneExt":32,"email":32},"Yugang Diao, Dr.",{"facility":78,"status":79,"city":80,"state":81,"zip":82,"country":53,"countryCode":54,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Renji Hospital","RECRUITING","Shanghai","Shanghai Municipality","200127",{"type":56,"coordinates":84},[85,86],121.45806,31.22222,{"lat":86,"lon":85},[89],{"name":44,"role":40,"phone":41,"phoneExt":32,"email":45},{"type":91,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100544309","norepinephrine-infusion-combined-with-goal-directed-fluid-therapy-in-patients-undergoing-kidney-transplantations-100544309",false,"NCT06367205","Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations","Norepinephrine Infusion Combined With Goal-directed Fluid Therapy Reduces Delayed Graft Function Incidence in Patients Undergoing Kidney Transplantations: a Randomized Multicenter Clinical Trial","Inclusion Criteria:\n\n1. Recipients aged 18 years or older\n2. Scheduled to undergo kidney transplantations under general anesthesia\n3. Cadaveric kidney transplantations\n4. Sign the informed consent form\n\nExclusion Criteria:\n\n1. Donors aged under 18 years\n2. Donor kidneys classified as Maastricht category I or II\n3. Contraindications to radial artery catheterization\n4. Pregnancy\n5. Cardiac dysfunction (exercise tolerance less than 4 METS)\n6. Severe liver dysfunction (Child Pugh C-grade)\n7. Respiratory diseases with tidal volume intolerance exceeding 8ml\u002Fkg\n8. Severe arrhythmias, including atrial fibrillation, frequent atrial or ventricular premature beats, moderate or severe aortic and mitral regurgitation\n9. Double-kidney transplantations\n10. Simultaneous organ or additional surgeries during kidney transplantations\n11. Repeat kidney transplantations\n12. Concurrent participation in other clinical trials\n13. Patients deemed ineligible by researchers","ALL","18 Years",{"count":102,"type":103},380,"ESTIMATED","INTERVENTIONAL",[106],"NA","Delayed graft function (DGF), delineated by the necessity for dialytic intervention within the initial week post-transplantation, afflicts approximately 20%-50% of recipients. The primary objective of this study is to investigate the potential efficacy of norepinephrine infusion in conjunction with goal-directed fluid therapy (GDFT) in mitigating the occurrence of DGF among individuals undergoing kidney transplantations. The findings of this investigation have the potential to advance the field of perioperative care in kidney transplantations by providing insights into optimized management strategies.",[109,110,111],"Delayed Graft Function","End Stage Renal Disease","Kidney Transplantation",[113,114,115],"Norepinephrine","Goal-directed fluid therapy","Randomized controlled trial","2024-04-15",{"date":118,"type":119},"2024-04-16","ACTUAL",{"date":121,"type":119},"2024-03-01",{"date":123,"type":103},"2026-06-30",{"name":5,"class":6},3]